A Clear Vision
Our vision is a future where earlier detection and individualized treatment will stop vision loss in its tracks, protecting and preserving eyesight, and way of life.
Search
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Facts About Asthma
Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.
The liver and its vital connection to our overall health
How health of the liver impacts our interconnected cardiovascular, renal, metabolic system and suffering and can have several comorbidities like obesity.
Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Leticia develops product medical strategies
Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Women in STEM: Passion for science
Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.
Eyes on Retina. The Podcast
Hear from experts and people living with retinal diseases such as wet age-related macular degeneration (AMD), stargardt disease and diabetic retinopathy.
vaxxitek® hvt + ibd + nd
Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Health for all: How can we contribute to inclusive access?
What drives us to improve the health of humans and animals worldwide
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
Connect the Docs
Experts discuss interconnectivitiy of heart failure, diabetes, and kidney disease and the importance of early diagnosis.
GPP: there is more than you see
Generalized Pustular Psoriasis is a rare neutrophilic skin condition. Watch an animation to learn about its recurrent nature and how it affects people
The Unwearable Collection™: Fashion Inspired by GPP
An introduction to The Unwearable Collection™: fashion inspired by the experiences of living with GPP, designed by Bart Hess
Facts About IPF
IPF is a debilitating and fatal lung disease.
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
We nurture innovative ideas
At Boehringer Ingelheim, we know to really make a difference we need to innovate. That’s why we embrace and invest in innovation every single day.
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
Lady, a guide dog in the office
A great partnership between a Boehringer Ingelheim employee and her guide dog at work. Their relationship goes beyond the human-animal bond.
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Shared science for the best cat diabetes management
Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.